Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Current Assets (2016 - 2025)

Historic Current Assets for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $29.9 million.

  • Cumberland Pharmaceuticals' Current Assets fell 1503.26% to $29.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.9 million, marking a year-over-year decrease of 1503.26%. This contributed to the annual value of $36.5 million for FY2024, which is 206.57% up from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its Current Assets stood at $29.9 million for Q3 2025, which was down 1503.26% from $31.2 million recorded in Q2 2025.
  • In the past 5 years, Cumberland Pharmaceuticals' Current Assets registered a high of $49.4 million during Q1 2021, and its lowest value of $29.9 million during Q3 2025.
  • Its 5-year average for Current Assets is $40.8 million, with a median of $43.7 million in 2023.
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Current Assets soared by 1038.51% in 2021, and later crashed by 2214.03% in 2023.
  • Cumberland Pharmaceuticals' Current Assets (Quarter) stood at $45.7 million in 2021, then grew by 0.4% to $45.9 million in 2022, then fell by 22.14% to $35.7 million in 2023, then rose by 2.07% to $36.5 million in 2024, then decreased by 17.87% to $29.9 million in 2025.
  • Its Current Assets stands at $29.9 million for Q3 2025, versus $31.2 million for Q2 2025 and $31.9 million for Q1 2025.